This study investigated the rates of cardiovascular events, predictive factors, and treatment patterns for blood pressure-lowering therapy in a population eligible for dual therapy. The study analyzed data from a 15-year period and identified individuals with hypertension who qualified for dual therapy according to guidelines. The primary endpoint was a composite of non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure, and cardiovascular death. The secondary endpoint was all-cause death. The study found that patients with hypertension eligible for dual therapy had a high risk of cardiovascular events and death, particularly those with atherosclerotic cardiovascular disease or diabetes. The study also revealed that monotherapy was the most common treatment pattern, deviating from guidelines. The findings emphasize the importance of timely initiation of dual blood pressure-lowering therapy to reduce risk in this population, particularly in patients with comorbidities.
